Daigneault Alessandra

General Counsel & SecretaryNRX Pharmaceuticals, Inc. (NRXP) · full profile →Form 4 · filed Nov 2, 2021
Net Selling
Open-Market Buys
$0
Open-Market Sells
$442K
Net Open-Market Flow
-$442K
Transactions
10
4 non-derivative · 6 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Sep 2, 2021Option exercise(M)13K$3.07$40K32K
Sep 2, 2021Option exercise(M)18K$3.07$57K18K
Aug 23, 2021Sell(S)34K$13.11$442K0
Aug 19, 2021Option exercise(M)27K$3.07$84K34K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Sep 2, 2021Grant(A)8K$034K
Sep 2, 2021Conversion(C)21K$3.07$63K29K
Sep 2, 2021Grant(A)10K$026K
Sep 2, 2021Conversion(C)29K$3.07$89K72K
Aug 19, 2021Grant(A)16K$016K
Aug 19, 2021Conversion(C)43K$3.07$132K101K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale
A
Grant / award
C
Conversion of a derivative

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950142-21-003504) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

Build

Build on these Form 4 transactions

The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.